drugset / Trial / NCT06825884

Use of Extracellular Vesicles (EV) for Diabetic Foot Ulcers

NCT06825884 ↗

Phase 1 Active not recruiting 10 enrolled University of Jordan Abdalla Awidi Abbadi, MD · collab
NaSingle-groupOpen-labelTreatment

Summary

Diabetes Mellitus is a common chronic medical condition that requires complex care strategies. Treatment includes methods to reduce glycemic burden and maintain glycemic control in the patient to prevent symptoms of hyperglycemia and reduce microvascular complications. In the case of patients with diabetes mellitus, wound healing, skin re- epithelization and skin integrity restoration are compromised, leading to chronic cutaneous ulcers such as diabetic foot ulcers. As much as 15% of all diabetic patients manifest diabetic foot ulcers. Moreover, 84% of all diabetes related lower leg amputations are anticipated to the result of diabetic foot ulcers. Compromised chronic cutaneous ulcer healing may result from cytokines, growth factor deficits, and insufficient angiogenesis process.

Timeline

Start
2024-12-01
Primary completion
2027-12-31
Completion
2028-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Extracellular micro vesicles Unknown 5 ml Other

Indications